Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab
Identifieur interne : 002837 ( Main/Exploration ); précédent : 002836; suivant : 002838Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab
Auteurs : Mai Tt Nguyen [Danemark] ; Jan P Denphant [Danemark] ; Pernille Ravn [Danemark]Source :
- BMJ Case Reports [ 1757-790X ] ; 2013.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Anticorps monoclonaux humanisés, Antirhumatismaux.
- Adulte d'âge moyen, Femelle, Humains, Indice de gravité médicale, Infections à staphylocoques, Mâle, Sujet âgé.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemically induced : Staphylococcal Infections.
- Teeft :
- Adverse effect, Aged, Aureus, Aureus infection, Aureus infections, Case reports, Early treatment, Female, Further permission, Health staff, Humans, Infection, Infectious diseases, Invasive, Male, Medication history, Middle Aged, Mild symptoms, Nguyen, Possible pathogenesis, Postmarketing, Prosthesis, Prosthetic, Prosthetic joints, Reactive protein, Rheumatoid, Rheumatoid arthritis, Right elbow, Severity of Illness Index, Staphylococcus, Staphylococcus aureus infection, Systematic postmarketing studies, Tocilizumab, University hospital.
Abstract
We report three cases of severe disseminated Staphylococcus aureus infection in patients with rheumatoid arthritis (RA) treated with tocilizumab. Tocilizumab is a new drug, unknown to most internists, and injections given weeks before admission may not be considered by the patient as part of their ‘current medical treatment’, and the physician may not be aware that the patient is severely immunosuppressed. Severe infections in RA patients treated with tocilizumab may present with mild symptoms despite severe and disseminated infection and, as these patients are severely immunodeficient-intensive diagnostic work-up and early treatment should be performed. Systematic postmarketing studies are needed to clarify if there is a true increased risk of disseminated S aureus infections. We suggest caution when prescribing tocilizumab to patients with prosthetic joints and/or prior invasive S aureus infections and that patients are taught to inform health staff about their medication history and their increased risk of infection.
Url:
DOI: 10.1136/bcr-2012-007413
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000342
- to stream Istex, to step Curation: 000342
- to stream Istex, to step Checkpoint: 000328
- to stream PubMed, to step Corpus: 001745
- to stream PubMed, to step Curation: 001745
- to stream PubMed, to step Checkpoint: 001487
- to stream Ncbi, to step Merge: 000721
- to stream Ncbi, to step Curation: 000721
- to stream Ncbi, to step Checkpoint: 000721
- to stream Main, to step Merge: 002851
- to stream Main, to step Curation: 002837
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab</title><author><name sortKey="Nguyen, Mai Tt" sort="Nguyen, Mai Tt" uniqKey="Nguyen M" first="Mai Tt" last="Nguyen">Mai Tt Nguyen</name></author><author><name sortKey="P Denphant, Jan" sort="P Denphant, Jan" uniqKey="P Denphant J" first="Jan" last="P Denphant">Jan P Denphant</name></author><author><name sortKey="Ravn, Pernille" sort="Ravn, Pernille" uniqKey="Ravn P" first="Pernille" last="Ravn">Pernille Ravn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F2A1E906E556D20B9699AFBAF7A155D58677EFD0</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/bcr-2012-007413</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-G1FNN6MQ-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000342</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000342</idno><idno type="wicri:Area/Istex/Curation">000342</idno><idno type="wicri:Area/Istex/Checkpoint">000328</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000328</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:23283607</idno><idno type="wicri:Area/PubMed/Corpus">001745</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001745</idno><idno type="wicri:Area/PubMed/Curation">001745</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001745</idno><idno type="wicri:Area/PubMed/Checkpoint">001487</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001487</idno><idno type="wicri:Area/Ncbi/Merge">000721</idno><idno type="wicri:Area/Ncbi/Curation">000721</idno><idno type="wicri:Area/Ncbi/Checkpoint">000721</idno><idno type="wicri:Area/Main/Merge">002851</idno><idno type="wicri:Area/Main/Curation">002837</idno><idno type="wicri:Area/Main/Exploration">002837</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab</title><author><name sortKey="Nguyen, Mai Tt" sort="Nguyen, Mai Tt" uniqKey="Nguyen M" first="Mai Tt" last="Nguyen">Mai Tt Nguyen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Infectious Diseases, University Hospital, Odense</wicri:regionArea><wicri:noRegion>Odense</wicri:noRegion></affiliation></author><author><name sortKey="P Denphant, Jan" sort="P Denphant, Jan" uniqKey="P Denphant J" first="Jan" last="P Denphant">Jan P Denphant</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Rheumatology, University Hospital, Gentofte</wicri:regionArea><wicri:noRegion>Gentofte</wicri:noRegion></affiliation></author><author><name sortKey="Ravn, Pernille" sort="Ravn, Pernille" uniqKey="Ravn P" first="Pernille" last="Ravn">Pernille Ravn</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Infectious Diseases, University Hospital, Hillerød</wicri:regionArea><wicri:noRegion>Hillerød</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">BMJ Case Reports</title><title level="j" type="abbrev">BMJ Case Reports</title><idno type="eISSN">1757-790X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2013">2013</date><biblScope unit="volume">2013</biblScope></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (adverse effects)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Staphylococcal Infections (chemically induced)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (effets indésirables)</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à staphylocoques ()</term><term>Mâle</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse effect</term><term>Aged</term><term>Aureus</term><term>Aureus infection</term><term>Aureus infections</term><term>Case reports</term><term>Early treatment</term><term>Female</term><term>Further permission</term><term>Health staff</term><term>Humans</term><term>Infection</term><term>Infectious diseases</term><term>Invasive</term><term>Male</term><term>Medication history</term><term>Middle Aged</term><term>Mild symptoms</term><term>Nguyen</term><term>Possible pathogenesis</term><term>Postmarketing</term><term>Prosthesis</term><term>Prosthetic</term><term>Prosthetic joints</term><term>Reactive protein</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Right elbow</term><term>Severity of Illness Index</term><term>Staphylococcus</term><term>Staphylococcus aureus infection</term><term>Systematic postmarketing studies</term><term>Tocilizumab</term><term>University hospital</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à staphylocoques</term><term>Mâle</term><term>Sujet âgé</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">We report three cases of severe disseminated Staphylococcus aureus infection in patients with rheumatoid arthritis (RA) treated with tocilizumab. Tocilizumab is a new drug, unknown to most internists, and injections given weeks before admission may not be considered by the patient as part of their ‘current medical treatment’, and the physician may not be aware that the patient is severely immunosuppressed. Severe infections in RA patients treated with tocilizumab may present with mild symptoms despite severe and disseminated infection and, as these patients are severely immunodeficient-intensive diagnostic work-up and early treatment should be performed. Systematic postmarketing studies are needed to clarify if there is a true increased risk of disseminated S aureus infections. We suggest caution when prescribing tocilizumab to patients with prosthetic joints and/or prior invasive S aureus infections and that patients are taught to inform health staff about their medication history and their increased risk of infection.</div></front></TEI><affiliations><list><country><li>Danemark</li></country></list><tree><country name="Danemark"><noRegion><name sortKey="Nguyen, Mai Tt" sort="Nguyen, Mai Tt" uniqKey="Nguyen M" first="Mai Tt" last="Nguyen">Mai Tt Nguyen</name></noRegion><name sortKey="P Denphant, Jan" sort="P Denphant, Jan" uniqKey="P Denphant J" first="Jan" last="P Denphant">Jan P Denphant</name><name sortKey="Ravn, Pernille" sort="Ravn, Pernille" uniqKey="Ravn P" first="Pernille" last="Ravn">Pernille Ravn</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002837 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002837 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F2A1E906E556D20B9699AFBAF7A155D58677EFD0
|texte= Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab
}}
| This area was generated with Dilib version V0.6.34. |  |